Cartesian Therapeutics, Inc. — Director's Dealing 2016

Jun 22, 2016

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: SELECTA BIOSCIENCES INC (SELB)
CIK: 0001453687
Period of Report: 2016-06-21

Reporting Person: Nanodimension Management Ltd (10% Owner)
Reporting Person: Nanodimension Limited Partnership (10% Owner)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	23167	Indirect

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Series B Convertible Preferred Stock	$		Common Stock (315729)		Indirect
Series C Convertible Preferred Stock	$		Common Stock (94183)		Indirect
Series D Convertible Preferred Stock	$		Common Stock (83596)		Indirect
Series E Convertible Preferred Stock	$		Common Stock (93078)		Indirect
Common Warrants	$17.55	2018-07-24	Common Stock (7007)		Indirect

Footnotes

F1: Held by NanoDimension L.P. ("ND LP"). NanoDimension Management Ltd., or ND GP, serves as the general partner of ND LP and possesses the power to direct the voting and disposition of the shares owned by ND LP and may be deemed to have indirect beneficial ownership of the shares held by ND LP. ND GP disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein. Jonathan Nicholson and Richard Coles are the members of the board of directors of ND GP and share voting and dispositive power over the shares held by ND LP. Each reporting person disclaims beneficial ownership of the securities reported herein, except to the extent of their respective pecuniary interest therein.

F2: The preferred stock is convertible at any time, at the holder's election and has no expiration date. The preferred stock will automatically convert into common stock upon the closing of the Issuer's initial public offering.